Pharmacologic Control of Wound Healing in Glaucoma Filtration Surgery

Journal of Ocular Pharmacology

Volumn 5, Issue 2, 1989, Pages 155-179

  Tahery, Moise M ^a   Lee, David A ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPROPIONITRILE; ANTINEOPLASTIC AGENT; FIBRINOLYTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; STEROID;

GLAUCOMA SURGERY; HUMAN; NONHUMAN; REVIEW; WOUND HEALING;

ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; DRUG ADMINISTRATION ROUTES; FIBRINOLYTIC AGENTS; FIBROBLASTS; FILTRATION; GLAUCOMA; HUMAN; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; SURGICAL PROCEDURES, OPERATIVE; WOUND HEALING;

EID: 0024344378     PISSN: 87563320     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.1989.5.155     Document Type: Article

References (233)

1. Dvorak H.F., McDonaugh J.: Regulation of extravascular coagulation by microvascular permeability. Science 227:1059–1061; 1985.
2. Tsao B.T., Fair D.S., Curtiss L.K., Edginston T.S.: Monocytes can be induced by lipopolysaccharide-triggered T lymphocytes to express functional factor VII/ VIIa protease activity. J. Exp. Med. 159:1042–1057; 1984.
3. Ramachandron G.N., Reddi A.H.: Biochemistry of Collagen, Plenum Press, New York and London. 1976.
4. Boucek R.J.: Factors affecting wound healing, Otol Clin. North Am. 17(2):243–264; 1984.
5. Majno G., Gilmore V., Leventhal M.: On the mechanism of vascular leakage caused by histamine-type mediators. Circ. Res. 21:833–847; 1967.
6. Samuelsson B., Golyne M., Granstrom E., Hamberg M., Hammarstrom S., Malmsten C.: Prostaglandins and thromboxanes. Ann. Rev. Biochem. 47:997–1029; 1978.
7. Palmer R.M.T., Stepney R., Higgs G.A., Eakins K.E.: Chemotactic activity of arachidonic acid lipoxygenase products on leukocytes from different species. Prostaglandins 20:411–418; 1980.
8. Robbins S.L., Cotran R.S., Kumar V.: Pathologic basis of disease. 3rd edition. W.B. Saunders Company p.53–56 1984.
9. Dvorak H.F.: Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Eng. J. Med. 315(26):1650–1659; 1986.
10. Dvorak H.F., Orenstein N.S., Carvalho A.C., Churchill W.H., Dvorak A.M., Galli S.J., Feder J., Bitzer A.M., Rypysc J., Giovinco P.: Induction of a fibrin-gel investment: An early event in line 10 hepatocarcinoma growth mediated by tumor-secreted products. J. Immunol. 122:166–174; 1979.
11. Clark R.A.F., Winn H.J., Dvorak H.F., Colvin R.B.: Fibronectin beneath re-epithelializating epidermis in-vivo: sources and significance. J. Invest. Dermatol, 80:026S-30S; 1983.
12. Grinnell F.: Fibronectin and wound healing. J. Cellular Biochem. 26(2):107–116: 1984.
13. Mosher D.F.: Fibronectin. Prog. Hemost. Thromb. 5:111–151; 1980.
14. Kurkinen M., Vaheri A., Roberts P.J., Stenman S.: Sequential appearance of fibronectin and collagen in experimental granulation tissue. Lab. Invest. 43:47–51; 1980.
15. McDonald J.A., Kelley D.G., Broekelmann T.J.: Role of fibronectin in collagen deposition: Fab to the gelatin-binding domain of fibronectin inhibits both fibronectin and collagen organization in fibroblast extracellular matrix. J. Cell Biol. 92:485–504; 1982.
16. Ross R., Raines E.W., Bowen-Pope D.F.: The biology of platelet-derived growth factor. Cell 46:155–169; 1986.
17. Tracy P.B., Nesheim M.E., Mann K.G.: Coordinate binding factor Va and factor Xa to the unstimulated platelet. J. Biol Chem. 256:743–751; 1981.
18. Sakariassen K.S., Bolhus P.A., Sixma J.J.: Human blood platelet adhesion to artery subendothelium is mediated by factor VM-Von Willebrand factor bound to the subendothelium. Nature 279:636–641: 1979.
19. Hamberg M., Svensson J., Samuelsson B.: Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA., 72:2994–2998; 1975.
20. Kulkarni P.S., Srinivasan B.D.: Steroidal and nonsteroidal anti-inflammatory drugs in ocular inflammation. Ocul. Inflam. Therap. 1:11–18; 1983.
21. Tzeng D.Y., Deuel T.F., Huang J.S., Baehner R.L.: Platelet-derived growth factor promotes human peripheral monocyte activation. Blood 66:179–183, 1984.
22. Bauer E.A., Cooper T.W., Huang J.S., Altman J., Deuel T.F.: Stimulation of in vitro human skin collagenases expression by platelet-derived growth factor. Proc. Natl. Acad. Sci. USA., 82:4132–4136; 1985.
23. Canalis E.: Effect of platelet-derived growth factor on DNA and protein synthesis in cultured rat calvaría. Metabolism 30:970–975; 1981.
24. Bach R., Nemerson Y., Konigsberg W.: Purification and characterization of bovine tissue factor J. Biol Chem. 256:8324–8331; 1981.
25. Maynard J.R., Heckman C.A., Pitlick F.A., Nemerson Y.: Association of tissue factor activity with the surface of cultured cells. J. Clin. Invest. 55:814–824; 1975.
26. Jarstrand C., Ahlgren T., Berghen L.: Fibronectin increases the motility, phagocytosis, and NBT (nitroblue tetrazoliuml-reduction of granulocytes. J. Clin. Lab. Immunol. 8:59–63; 1982.
27. Simpson D.M., Ross R.: The neutrophilic leukocyte in wound repair: a study with antineutrophil serum. J. Clin. Invest. 51:2009–2023; 1972.
28. Ross R.: The fibroblast and wound repair. Biol Rev. 43:51–96; 1968.
29. Horowitz A.L., Hance A.J., Crystal R.G.: Granulocyte collagenase: selective digestion of type I relative to type III collagen. Proc. Natl Acad. Sci. USA., 74:897–901; 1977.
30. Norris D.A., Clark R.A.F., Swigart L.M., Huff J.C., Weston W.L.: Fibronectin fragment(s) are chemotactic for human peripheral blood monocytes. J. Immunol 129:1612–1618; 1982.
31. Volkman A.: A current prespective on monocytopoiesis. Curr. Top. Pathol 54:76–94; 1971.
32. Leibovich S.J., Ross R.: The Role of The Macrophage in Wound Healing: A study with hydrocortisone and antimacrophage serum. Am. J. Pathol. 78:71–100; 1975.
33. Virolainen M.: Hematopoietic origin of macrophages as studied by chromosome markers in mice. J. Exp. Med. 127:943–951; 1968.
34. Dinarello C.A.: Interleukin-I. Rev. Infect. Dis. 6:51–95; 1984.
35. Knighton D.R., Hunt T.K., Scheuenstuhl H., Halliday B.J.: Oxygen Tension Regulates the Expression of Angiogenesis Factor by Macrophages. Science 221:1283–1285; 1983.
36. Tsukamoto Y., Helsel W.E., Wahel S.M.: Macrophage production of fibronectin, a chemoattractant for fibroblasts. J. Immunol. 127:673–678; 1981.
37. Boucek R.J., Alvarez T.R.: 5 Hydroxytryptamine: a cytospecific growth stimultor of cultured fibroblasts. Science 167:898; 1970.
38. Folkman J., Klagsburn M.: Angiogenic Factors. Science 235:442–447; 1987.
39. Ausprunk D.H., Folkman J.: Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during tumor angiogenesis. Microvasc. Res. 14:53–65; 1977.
40. Gospodarowicz D., Bialecki H., Greenburg G.: Purification of fibroblast growth factor from bovine brain. J. Biol. Chem. 253:3736–3743; 1978.
41. Maciag T., Cerundolo I.S., Kelley P.R., Forand R: An endothelial cell growth factor from bovine hypothalamus: Identification and partial characterization. Proc. Natl. Acad. Sci. USA. 76:5674–5678; 1979.
42. Strydom D.J., Fett J.W., Lobb R.R., Alderman E.M., Bethune J.L., Riordan J.F., Vallee B.L.: Amino acid sequence of human tumor derived angiogenin. Biochemistry 24:5486–5494; 1985.
43. Marquardt H., Hunkapiller M.W., Hood L.E., Todaro G.J.: Rat transforming growth factor type I: Structure and relation to epidermal growth factor. Science 223:1079–1082: 1984.
44. Derynck R., Jarret J.A., Chen E.Y., Eaton D.H., Bell J.R., Assion R.K., Roberts A.B., Sporn M.B., Goeddel D.V.: Human transforming growth factor-B complementary DNA sequence and expression in normal and transformed cells. Nature 316:701–705; 1985.
45. Muthukkaruppan V.R., Auerbach R.: Angiogenesis in mouse cornea. Science 205:1416–1418; 1979.
46. Form D.M., Auerbach R.: PGE2 and angiogenesis (41548). P. Soc. Exp. Med. 172:214–218; 1983.
47. Banda M.J., Knighton D.R., Hunt T.K., et al: Isolation of a nonmitogenic angiogenesis factor from wound fluid. Proc. Natl. Acad, Sci. USA., 79:7773–7777; 1982.
48. Chvapil M., Koopmann C.F.: Scar formation: Physiology and pathology states. Otolaryngeal Clin. North Am. 17(2):265–272; 1984.
49. Gabbiani G., Montandon D.: Reparative processes in mammalian wound healing: The role of contractile phenomena. Int. Rev. Cytol. 48:187–219; 1977.
50. Rhoeds R.E., Udenfriend S.: Purification and properties of proline hydroxylase from new-born rat skin. Arch. Biochim. Biophys. 139:329–339; 1970.
51. Prockop D.J., Keinstein E., Mulveny T.: Hydroxylation of lysine in a polypepetide precursor of collagen. Biochim. Biophys. Res. Commun. 22:124–128; 1966.
52. Dehm P., Prockop D.J.: Time lag in the secretion of collagen by matrix-free tendon cells and inhibition of the secretory process by colchicine and vinblastine. Biochim. Biophys. Acta. 264:375–382, 1972.
53. Jimenez S.A., Dehm P., Prockop D.J.: Further evidence for a transport form of collagen. Its extrusion and extracellular conversion to tropocollagen in embryonic tendon. FEBS Lett., 17:245–248; 1971.
54. Lapiere CM., Lenares A., Kohn L.D.: Procollagen peptidase: An enzyme excising the coordination peptides of procollagen. Proc. Natl. Acad. Sci. USA. 68:3054–3058: 1971.
55. Guber S., Ross R.: The myofibroblast. Surg. Gyn. Obstet. 146:641–649: 1978.
56. Gabbiani G., LeLouis M., Bailey A.J., Bazin S., Delaunay A.: Collagen and myofibroblasts of granulation tissue. Virchow's Arch. Biol. Cell Pathol. 21:133–145: 1976.
57. Snowden J.M.: Wound closure: analysis of the relative contributions of contraction and epithelialization. J. Surg. Res. 37(6):453–463; 1984.
58. Gabbiani G., Ryan G.B., Majno G.: Presence of modified fibroblasts in granulation tissue and their possible role in wound contracture. Experimentia 27:549–550; 1971.
59. James D.W., Taylor J.F.: The stress developed by sheets of chick fibroblasts in vitro. Exp. Cell Res. 54:107–110; 1969.
60. Montandon D., D' Andiran G., Gabbiani G.: The mechanisms of wound contraction and epithelialization: clinical and experimental studies. Clin. Plast. Surg. 4:325–346; 1977.
61. Lambert W.C., Cohen P.J., Klein K.M., Lambert M.W.: Role of the epidermis and other epithelia in wound healing: selected concepts. Clin. Dermatol. 2(3):24–33; 1984.
62. Gabbiani G., Chaponjier C., Huttner I.: Cytoplasmic filaments and gap junction on epithelial cells and myofibroblasts during wound healing. J. Cell Biol. 76:561–568; 1978.
63. Grillo H.C., Gross J.: Collagenolytic activity and epithelial-mesenchymal interaction in healing mammalian wounds. J. Cell, Biol. 23:39A; 1964.
64. Gilchrest B.A., Calhoan J.K., Maciag T.: Attachment and growth of human keratinocytes in a serum-free environment. J. Cell Physiol. 112:197–206; 1982.
65. Donaldson D.J., Mahan J.T., Hasty D.L., McCarthy J.B., Furcht L.T.: Location of a fibronectin domain involved in newt epidermal cell migration. J. Cell Biol. 101(1):73–78; 1985.
66. Krawczyk W.S.: Pattern of epidermal cell migration during wound healing. J. Cell Biol. 49:247–263; 1970.
67. Norrby K.: On the 48/80-induced secretions of tissue mast cells and its mitogenic effect on nearby cells in the intact rat. Virchow's Arch. Cell Pathol. 38:57–65; 1981.
68. Norrby K.: Mast cell histamine, a local mitogen acting via H-2 receptors in nearby tissue cells. Virchow's Arch. Cell Pathol. 34:13–20; 1980.
69. Karasek M.A., Charlton M.E.: Growth of post embryonic skin epithelial cells on collagen gels. J. Invest. Dermatol. 56:205–210; 1971.
70. Alvarez O.M., Mertz P.M., Eaglstein W.H.: The effect of the proline analogue L-azetidine-2-carvoxylic acid (LACA)on epidermal and dermal wound repair. Plast. Reconstr. Surg. 69:284–289; 1982.
71. Alvarez O.M., Mertz P.M., Smerbeck B.S., Eaglstein W.H.: The healing of superficial skin wounds is stimulated by external electric current. J. Invest. Dermatol. 81:144–148; 1971.
72. Ariyan S., Enriquez R., Krizek T.J.: Wound contraction and fibrocontractive disorders. Arch. Surg. 113:1034–1046; 1978.
73. Dabelsteen E., Kremenak C.R.: Demonstration of actin in the fibroblast of healing palatal wounds. Plast. Reconstr. Surg. 62:429–435; 1978.
74. Madden J.W., Morton D., Peacock E.E.: Contraction of experimental wounds: I. Inhibiting wound contraction by using a topical smooth muscle antagonist. Surgery 76:8–15; 1974.
75. Gabbiani G., Hirschel B.J., Ryan G.B., Statkov P.R., Majno G.: Granulation tissue as a contractile organ. A study of structure and function. J. Exp. Med. 135:719–734; 1972.
76. Squier C.A.: The effect of stretching on formation of myofibroblasts in mouse skin. Cell Tissue Res. 220:325–335; 1981.
77. Becker C.G., Hardy A.M.: Contracted protein in endothelial cells of cerebral arteries and arterioles. Comparison of normotensive and malignant hypertensive states. Circulation 48(supplement IV):44; 1973.
78. Cottier H., Dreher R., Keller H.U., Roos B., Hess M.W.: Cytokinetic aspects of wound healing. Lonacre JJ (ed). The ultrastructure of collagen. Charles C. Thomas, Springfield, IL, 1976.
79. Mellstrom K., Hoglund L., Nister M., Heldin C.H., Westermark B., Lindberg U.: The effect of platelet-derived growth factor on morphology and motility of human glial cells. J. Muse. Res. Cell Motil 4:589–609; 1983.
80. Abercrombie M., Flint M., James D.W.: Collagen formation and wound contraction during repair of small excised wounds in the skin of rats. J. Embryol. Exp. Morphol. 2:264–274; 1954.
81. Lindquist G.: The healing of skin defects., An experimental study in the white rat. Acta Chir. Scand. 94(suppl. 107):163: 1946.
82. Abercrombie M., James D.W., Newcombe J.F.: Wound contraction in rabbit skin, studied by splinting the wound margins. J. Anat. 94:170–182; 1960.
83. Wang K., Ash J.F., Singer S.J.: Filamin, a new high-molecular-weight protein found in smooth muscle and non-muscle cells. Proc. Natl. Acad. Sci. 72:4483–4486; 1975.
84. Rudolph R., Suzuki M., Guber S., Woodward M.: Control of contractile fibroblasts by skin grafts. Surg. Forum 28:524–527; 1977.
85. James D.W.: Intussusceptive growth of skin islands within wounds. J. Anat. 93:101–109; 1959.
86. Searls J.C., Kremenak C.R., Rittman B.R.: Quantitative characterization of changes in cellularity and collagen fiber size in contracting palatal wounds. Cleft Palate J. 16:373–380; 1979.
87. Olin W.H., Morris J., Geil J., Pratt S., Kremenak C.: Contraction of mucoperiosteal wounds after palate surgery in beagle pups. J. Dent. Res. 53 (Special Issue):149; 1974.
88. Dvorak H.F., Harvey V.S., McDonaugh J.: Quantitation of fibrinogen influx and fibrin deposition and turnover in line 1 and line 10 guinea pig carcinomas. Cancer Res. 44:3348–3354; 1984.
89. Dvorak H.F., From D.M., Manseau E.J., Smith B.D.: Pathogenesis of desmoplasia. I. Immunofluorescence identification and localization of some structural proteins of line 1 and line 10 guinea pig tumors and of healing wounds. JNCI 73:1195–1205; 1984.
90. Peacock Jr. E.E., Van Winkle Jr. W.: Wound Repair (2nd ed.). Philadelphia, W. B. Saunders, 1976. Part II.
91. Shields M.B.: Textbook of glaucoma (2nd ed.), Kist K. ed., Williams and Wilkins, New York, 1987.
92. Eakins K.E.: Prostaglandin and non-prostaglandin breakdown of blood-aqueous barrier. In “The ocular and cerebrospinal fluid.” Exp. Eye Res. 25(Suppl.):483–498: 1977.
93. Eakins K.E., Atwal M., Bhattacherjee P.: Inactivation of prostaglandin El by ocular tissue in vitro. Exp. Eye Res. 19:141–146; 1974.
94. Flower R.J., Blackwell G.J.: Anti-inflammatory steroids induced biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature 278:456–459; 1979.
95. Hirata F., Schiffmann E., Venkatasubramanian K., Solomon D., Axelrod J.: A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc. Natl. Acad. Sci. USA, 77:2533–2536: 1980.
96. Long D.A.: The influence of corticosteroids on immunological responses to bacterial infection. Int. Arch. Allergy Appl. Immunol. 10:5–12; 1957.
97. Santamaría J.: Steroidal agents: Their systemic and ocular complications. Ocul Inflam. Therap. 1:19–26; 1983.
98. Liddle G.W.: Clinical pharmacology of the anti-inflammatory agents. Clin. Pharmacol Ther. 2:615–635; 1961.
99. Ketchel M.M.: Favour CB, Strugis SH: The in vitro action on leukocyte migration. J. Exp. Med. 107:211–218; 1958.
100. Giangiacomo J., Dueker D.K., Adelstein E.: The effect of subconjunctival triamcinolone administration on glaucoma filtration. I. Trabeculectomy following subconjunctival triamcinolone. Arch. Ophthalmol. 104:838–841: 1986.
101. Kulkarni P.S., Bhattacherjee P., Eakins K.E., Srinivasan B.D.: Anti-inflammatory effects of betamethasone phosphate, dexamethasone phosphate and indomethacin on rabbit ocular inflammation induced by bovine serum albumin. Current Eye Res. 1:43–47; 1981.
102. Starita R.J., Fellman R.L., Spaeth G.L., Poryzees E.M., Greenidge K.C., Traverso C.E.: Short-and long-term effects of postoperative corticosteroids on trabeculectomy. Ophthalmology 92:938–946; 1985.
103. Flower R.J., Vane J.R.: Some pharmacological and biochemical aspects of prostaglandin biosynthesis and its inhibition. In Prostaglandin Synthatase Inhibitors, HJ Robinson and JR Vane, Eds. Raven Press, New York, 1974, p.9.
104. Nozu K.: Flurbiprofen, a highly potent inhibitor of prostaglandin sythesis. Biochim. Biophys. Acta 529:493–496: 1978.
105. Higgs G.A., Flower R.J., Vane J.R.: A new approach to anti-inflammatory drugs. Biochem, Pharmacol. 28:1959: 1979.
106. Walker J.R., Dawson W.: Inhibitory effect of benoxyprofen and BW755C on rabbit PMN leukocyte lipoxygenase., In Inflammation: Mechanism and Treatments. (Proceedings on future trends in inflammation.)MTP, Lancaster, Pa., 1980.
107. Kulkarni P.S., Eakins K.E.: N-0164 inhibits generation of thromboxane A2 like activity from prostaglandin endoperoxides by human platelet microsomes. Prostaglandins 12:465; 1976.
108. Moncada S., Bunting S., Mullane K., Thorogood P., Vane J.R., Raz A.: Imidazole: A selective potent antagonist of thromboxane synthetase. Prostaglandins 13:611–618; 1977.
109. Allan G., Eakins K.E., Kulkarni P.S., Levi R.: Inhibition of thromboxane A2 biosynthesis in human platelets by burimamide. Br. J. Pharmacol. 71:157–164; 1980.
110. Moncada S., Needleman P., Bunting S., Vane J.R.: Prostaglandin endoperoxide and thromboxane generating system and their selective inhibition. Prostaglandins 12:323–329; 1976.
111. Parker C.W.: Leukotrienes: their metabolism, structure and role in allergic response., In Leukotrienes and Other Lipoxygenase Products, B. Samuelsson and R. Paoletti, Eds. Raven Press, New York. 1982, Vol. 9, p.115.
112. Bunting S., Gryglewski R., Moncada S., Vane J.R.: Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 12:897–913; 1976.
113. Snyder R.W., Lambrou F.H., Williams G.A.: Intraocular fibrinolysis with recombinant human tissue plasminogen activator. Experimental treatment in a rabbit model. Arch. Ophthalmol. 105:1277–1280; 1987.
114. Chapman-Smith J.S., Crock G.W.: Urokinase in the management of vitreous haemorrhage. Br. J. Ophthalmol. 61:500–505; 1977.
115. Friedman M.W.: Streptokinase in ophthalmology. Am. J. Ophthalmol. 35:1184–1187; 1952.
116. Leet D.M.: Treatment of total hyphemas with urokinase. Am. J. Ophthalmol. 84:79–84; 1977.
117. White W.F., Barlow G.H., Mozen M.M.: The isolation and characterization of plasminogen activators (urokinase)from human urine. Biochemistry 5:2160–2169; 1960.
118. Zamarron C., Lijnon H.R., Collen D.: Competitive inhibition by human plasma of the activation of plasminogen by pro-urokinase. Thromb. Haemost. 54(Suppl. l)(abstr.):102; 1985.
119. Lijnen H.R., Zamarron C., Collen D.: Prourokinase: Kinetics and mechanism of action. Thromb. Haemost. 54(Suppl. l)(abstr.):118; 1985.
120. Guriwich V., Pannell R., Louie S., Kelley P., Suddith A.L., Green Lee R.: Effective and fibrin specific clot lysis by a zymogen precursor form of urokinase (pro-UK). A study in vitro and in two animal species. J. Clin. Invest. 73:1731–1739; 1984.
121. Collen D., Stemp D., Van der Werf F., Jang I.K., Nobuhara M., Lijnen H.R.: Coronary thrombolysis in dogs with intravenously administered human pro-urokinase. Circulation 72(2):384–388; 1985.
122. Back N., Mink I.B.: Distribution and fate of I(131)-labeled component of the fibrinolysin system. Circ. Res. 9:1208–1216; 1966.
123. Blix S.: The effectiveness of activators in clot lysis, with special reference to fibrinolytic therapy. A new method for determination of preformed clot lysis. Acta Medica Scand. (suppl) 386; 1962.
124. Kosow D.P.: Kinetic mechanism of activation of human plasminogen by streptokinase. Biochemistry 14:4459–4465: 1975.
125. Lassen M.: Adsorption of plasminogen activator to fibrin. Acta Chemica. Scand. 12:1825; 1985.
126. Johnson A.J., McCarthy W.R.: The lysis of artificially induced intravascular clots in man by infusions of streptokinase. J. Clin. Invest. 38:1627–1643; 1959.
127. Bennet W.F.: Two forms of tissue plasminogen activator (t-PA) differ at a single glycosylation site. Thromb. Haemost. 50:106; 1983.
128. Pennica D., Holmes W.E., Kohr W.J., Harkins R.N., Vehar G.A., Ward C.A., Bennet W.F., Yelverton E., Seeburg P.H., Heyneker H.L., Goeddel D.V.: Cloning and expression of human tissue type plasminogen activator with DNA in E coli. Nature 301:214–221; 1983.
129. Hoylaerts M., Rijken O.C., LiJnen H.R., Collen D.: Kinetics of the activation of plasminogen by human tissue plasminogen activator: Role of fibrin. J. Biol. Chem. 257:2912–2919; 1982.
130. Rijkin D.C., Hoylaerts M., Collen D.: Fibrinolytic properties of one chain and two chain extrinsic (tissue type) plasminogen activator. J. Biol. Chem. 257:2920–2925; 1982.
131. Dano K., Andreason P.A., Grondahl-Hansen J., Kirstensen P., Nielsen L.S.: Plasminogen activators, tissue degradation and cancer. Adv. Cancer Res. 44:139–266; 1985.
132. Verstraete M., Collen D.: Thrombolytic therapy of the 80′s. Blood 67:1529–1541; 1986.
133. Im M.J., Hoopes J.E.: Energy metabolism in healing skin wounds. J. Surg. Res. 10:459–464; 1970.
134. Machemer R.: Massive periretinal proliferation: A logical approach to therapy. Trans. Am. Ophthalmol. Soc. 75:556–586; 1977.
135. Blumenkranz M.S., Claflin A., Hajek A.S.: Selection of therapeutic agents for intraocular proliferative disease. Cell culture evaluation. Arch. Ophthalmol. 102:598–604; 1984.
136. Ferguson M.K.: The effect of antineoplastic agents on wound healing. Surg. Gynecol. Obstet. 154:421–429; 1982.
137. Karppinen V., Myllarniemi H.: Vascular reactions in the healing laparotomy wound under cytostatic treatment. Acta Chir. Scand. 136:675–680; 1970.
138. Myllarniemi H., Petokallio P.: The effect of high dose cyclophosphamide therapy in the abdominal cavity of the rat: Adhesions and their vascular patterns. Ann. Chir. Gynecol. 63:238–245; 1974.
139. Mullen B.M., Mattox D.E., Von Hoff D.D., Hearne E.M.: The effects of preoperative adriamycin and dihydroxyathracenedione on wound healing. Laryngoscope 91:1436–1443; 1981.
140. Molteno A.C.B., Straughan J.L., Ancker E.: Control of bleb fibrosis after glaucoma surgery by anti-inflammatory agents. S. A. Med. J. 50:881–885: 1976.
141. Mallick K.S., Hajek A.S., Parrish R.K.: Fluorouracil (5-FU) and cytarabine (ara-C) inhibition of corneal epithelial cell and conjunctival fibroblast proliferation. Arch. Ophthalmol. 103:1398–1402; 1985.
142. Rich M.A., Saslaw L., Eidinoff M.L.: Some differences among various mammalian cell lines in reversal of growth inhibition by 5-fluorouracil. Proc. Soc. Exp. Biol. Med. 103:791–796; 1960.
143. Madoc-Jones H., Bruce W.R.: On the mechanism of the lethal action of 5-fluorouracil on mouse L cells. Cancer Res. 28:1976–1981; 1968.
144. Evans R.M., Laskin J.D., Hakala M.T.: Assessment of growth-limitation events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res. 40:4113–4122; 1980.
145. Gressel M.G., Parrish R.K., Folberg R.: 5-fluorouracil and glaucoma filtration surgery: I An animal model. Ophthalmology 91:378–383; 1984.
146. Heuer D.K., Parrish R.K., Gressel M.G., Hodapp E., Palmberg P.F., Anderson D.R.: 5-Fluorouracil and glaucoma filtering surgery. II. A pilot study. Ophthalmology 91:384–394; 1984.
147. Haidak D.J., Hurwitz B.S., Yeung K.Y.: Tear-duct fibrosis (dacryostenosis) due to 5-fluorouracil. Ann. Intern. Med. 88:657; 1978.
148. Caravella Jr L.P., Burns J.A., Zangmeister M.: Punctal-canalicular stenosis related to systemic fluorouracil therapy. Arch. Ophthalmol. 99:284–286: 1981.
149. Straus D.J., Mausolf F.A., Ellerby R.A., McCracken J.D.: Cicatricial ectropion secondary to 5-fluorouracil therapy. Med. Pediatr. Oncol. 3:15–19; 1977.
150. Blumenkranz M.S., Ophir A., Claflin A.J.: Fluorouracil for the treatment of massive preretinal proliferation. Am. J. Ophthalmol. 94:458–467; 1982.
151. Blumenkranz M., Hernandez E., Ophir A., Norton E.W.D.: 5-Fluorouracil: New applications in complicated retinal detachments for an established antimetabolite. Ophthalmology 91:122–130; 1984.
152. Friend J., Shapiro M.S., Thoft R.A., Parrish R.K., Gressel M.G.: Hypomitosis of ocular surface epithelium and persistent epithelial defect with 5-fluorouracil. Invest. Ophthalmol. Vis. Sci. 25(suppl.):77; 1984.
153. Silagi S.: Metabolism of 1-beta-arabino-furanosylcytosine in L cells. Cancer Res. 25:1446–1453; 1965.
154. Kaufman H.E., Capella J.A., Maloney E.D., Robbins J.E., Cooper G.M., Votila M.H.: Corneal toxicity of cytosine arabinoside. Arch. Ophthalmol. 72:535–540; 1964.
155. Hande K.R., Stein R.S., McDonough D.A., Greco F.A., Wolff S.N.: Effects of high-dose cytara-bine. Clin. Pharmacol. Ther. 31:669–674; 1982.
156. Wiedemann P., Lemmen K., Schmiedl R., Heimann K.: Intraocular daunorubicin for the treatment and prophylaxis of traumatic proliferative vitreoretinopathy. Am. J. Ophthalmol. 104:10–14; 1987.
157. Myers C.E., Corden B., Gianni L.: Antitumor antibiotics. I. Anthracyclines., In Chabner BA, Pinedi HM (eds): The Cancer Pharmacology Annual 2. Amsterdam, Elsevier, 1984, pp. 66–79.
158. Bunt A.H., Lund R.D.: Vinblastine-induced blockage of orthograde and retrograde axonal transport of protein in retinal ganglion cells. Exp. Neurol. 45:288–297; 1974.
159. Koerner F., Merz A., Gloor B., Wagner E.: Postoperative retinal fibrosis. A controlled clinical study of systemic steroid therapy. Graefes Arch. Clin. Exp. Ophthalmol. 219:268–271; 1982.
160. Clarkson J.M., Humphrey R.M.: The effect of adriamycin on cell cycle progression and DNA replication in chínese hamster ovary cells. Cancer Res. 37:200–205; 1977.
161. Priestley G.C.: Effect of corticosteroids on the growth and metabolism of fibroblasts culture from human skin. Br. J. Dermatol. 99:253–261; 1978.
162. Ehrlich H.P., Hunt T.K.: The effects of cortisone and anabolic steroids on the tensile strength of healing wounds. Ann. Surg. 170:203–206; 1969.
163. Laval J., Coles R.S.: Role of cortisone in glaucoma surgery. Experimental results. Arch Ophthalmol. 49:168–181; 1953.
164. Hial V., DeMello M.C.F., Horakova Z., Beaven M.A.: Antiproliferative activity of antiinflammatory drugs in two mammalian cell culture lines. J. Pharmacol. Exp. Ther. 202:446–454; 1977.
165. Blumenkranz M., Ophir A., Claflin A.: A pharmacologie approach to non-neoplastic intraocular proliferation. ARVO Abstracts. Invest. Ophthalmol. Vis. Sci. 20(suppl.):200: 1981.
166. Neupert G., Müller P.: Growth inhibition and morphological changes caused by indomethacin in fibroblasts in vitro. Exp. Pathol, 11:1–5; 1975.
167. Verdoorn C., Rnardel de Lavalette V.W., Dalma-Weizhausz J., Orr G.M., Srgente N., Ryan S.J.: Cellular migration, proliferation and contraction. Arch. Ophthalmol. 104:1216–1219; 1986.
168. Lemor M., Bustros S., Glaser B.M.: Low-dose colchicine inhibits astrocyte, fibroblast and retinal pigment epithelial cell migration and proliferation. Arch. Ophthalmol. 104:1223–1225; 1986.
169. Davidson C., Green W.R., Wong V.G.: Retinal atrophy induced by intravitreous colchicine. Invest. Ophthalmol. Vis. Sci. 24:301–311: 1983.
170. Borisy G.G., Taylor E.W.: The mechanism of action of colchicine: Binding of colchicine-H3 to cellular protein. J. Cell Biol. 34:525–533; 1984.
171. Schiff P.B., Horwitz S.B.: Taxol stabilizes microtubules in mouse fibroblast cells. Proc. Natl. Acad. Sci. USA, 77:1561–1565; 1980.
172. Antin P.B., Forry-Schaudies S., Friedman T.M., Tapscott S.J., Holtzer H.: Taxol induces postmitotic myoblasts to assemble interdigitating microtubule-myosin arrays that exclude actin filaments. J. Cell Biol. 90:300–308; 1981.
173. Kay J.S., Litin B.S., Woolfenden J.M.: Delivery of antifibroblast agents as adjuncts of filteration surgery. Part I- Periocular clearance of cobalt-57 bleomycin in experimental drug delivery: Pilot study in the rabbit. Ophthal Surg. 17(10):626–630: 1986.
174. Tanaka N., Yutaka U.: Effect of beta irradiation on the trephine wound in rabbit cornea. Acta Soc. Ophthalmol. Jpn 66:1090–1096; 1962.
175. Cohen L.B., Graham T.F., Fry W.E.: Beta irradiation. As an adjunct to glaucoma filtration surgery in the Negro. Am. J. Ophthalmol. 47:54–61;1959.
176. Ogino N., Masuda H., Abe Y.: Beta irradiation in filtering operations. Acta Soc. Ophthalmol. Jpn 70:1834–1839; 1966.
177. Ellis H.: The causes and prevention of intestinal adhesions. Br. J. Surg. 69:241–243; 1982.
178. Wilson M.R., Reaves H.: Additional comments on the effect of triamcinolone injection (letter). Arch. Ophthalmol. 105:1166; 1987.
179. Harris E.D., Krane S.M.: Effects of colchicine on collagenase in cultures of rheumatoid synovium. Arthritis Rheum. 14:669–684; 1971.
180. Ehrlich H.P., Grislis G., Hunt T.K.: Evidence for the involvement of microtubules in wound contraction. Am. J. Surg. 133:706–709; 1977.
181. Ball S.F., Morsey M.S., Tamaki K.: Triamcinolone and subconjunctival fibrosis in rabbits. Invest. Ophthalmol. Vis. Sci 27(suppl): 163, 1986.
182. Diegelmann R.F., Peterkofsky B.: Inhibition of collagen secretion from bone and cultured fibroblasts by microtubular disruptive drugs. Proc. Natl. Acad. Sci. USA. 69:892–896; 1972.
183. Peacock E.E.: Pharmacologie control of surface scarring in human beings. Ann. Surg. 193:592–597; 1981.
184. Peacock E.E., Madden J.W.: Some studies in the effects of B-aminopropionitrile in patients with injured flexor tendons. Surgery 66:215–223; 1969.
185. Moorhead L.C.: Inhibition of collagen cross-linking: A new approach to ocular scarring. Current Eye Res. 1:77–83; 1981.
186. Moorhead L.C., Smith J., Stewart R., Kimbrough R.: Effects of beta-aminopropionitrile after glaucoma filtration surgery: Pilot human trial. Ann. Ophthalmol. 19:223–225; 1987.
187. Albergoni V., Cassini A., Favero N., Rocco G.T.: Effect of penicillamine on some metals and metaloprotein in the rat. Biochem. Pharmacol 24:1131–1133; 1975.
188. Siegel R.C.: Collagen crosslinking effect of D-penicillamine on cross-linking in vitro. J. Biol Chem. 252:254–259; 1977.
189. Chen D.M., DiSabato G., Field L., Gallo A.A., Harshman S.: Some immunological effects of penicillamine. Clin. Exp. Immunol 30:317; 1977.
190. McGuigan J.B., Mason R.P., Sanchez R., Quigley H.A.: D-penicillamine and beta-aminopropionitrile effects on experimental filtering surgery. Invest. Ophthalmol. Vis. Sci. 28:1625–1629; 1987.
191. Burke J., Foster S., Herschler J.: Aqueous humor as a modulator of growth in fibroblast cultures. Current Eye Res. 2:835–841; 1983.
192. Kornbleuth W., Tenebaum E.: The inhibitory effect of aqueous humor on the growth of cells in tissue cultures. Am. J. Ophthalmol. 42:70–74; 1956.
193. Herschler J., Claflin A., Fiorentino G.: The effect of aqueous humor on the growth of subconjunctival fibroblasts in tissue culture and its implications for glaucoma surgery. Am. J. Ophthalmol. 89:245–249; 1980.
194. Radius R., Herschler J., Claflin A., Fiorentino G.: Aqueous humor changes after experimental filtering surgery. Am. J. Ophthalmol 89:250–254; 1980.
195. Elias J.A., Rossman M.D., Daniele R.P.: Inhibition of human lung fibroblast growth by mononuclear cells. Am. Rev. Respir. Dis. 125:701–705; 1982.
196. Magnuson N.S., Decker D.M., Perryman L.E.: Increased susceptibility of fibroblasts from horses with severe combined immunodeficiency to growth inhibition by 2-deoxyadenosine. Clin. Immunol. Immunopathol 29:391–402; 1974.
197. Korn J.H., Halushka P.V., LeRoy E.C.: Mononuclear cell modulation of connective tissue function: suppression of fibroblast growth by stimulation of endogenous prostaglandin production. J. Clin. Invest. 65:543–554; 1980.
198. Ahn S.S., Machleder H.I., Gupta R., Moore W.S.: Perigraft seroma: Clinical, histological, and serologie correlates. Am. J. Surg. 154:173–178; 1987.
199. Nagao T., Yamauchi K., Komatsuda M., Noguchi K., Shimizu M., Yonekura S., Nozaki H.: Inhibition of human bone marrow fibroblast colony formation by leukemic cells. Blood 62:1261–1265; 1983.
200. Steck P.A., Voss P.G., Wang J.L.: Growth control in cultured 3T3 fibroblasts., Assays of cell proliferation and demonstration of a growth inhibitory activity. J. Cell Biol. 83:562–575; 1979.
201. Wu C.H., Donovan C.B., Wu G.Y.: Evidence for pretranslational regulation of collagen synthesis by procollagen peptides. J. Bio. Chem. 261(23):10482- 10484; 1986. Part III.
202. Shields M.B., Bradbury M.J., Shelburne J.D., Bell S.W.: The permeability of the outer layers of limbus and anterior sciera. Invest. Ophthalmol Vis. Sci. 16:866–869; 1977.
203. Iliff C.E., Haas J.S.: Posterior lip sclerectomy. Am. J. Ophthalmol. 54:688–693; 1962.
204. Cairns J.E.: Trabeculectomy. Trans. Am. Acad. Ophthalmol. Otol. 75:1395; 1971.
205. Sugar H.S.: Limboscleral trephination. Am. J. Ophthalmol. 59:656–668; 1965.
206. Scheie H.G.: Retraction of scierai wound edges. Am. J. Ophthalmol. 45(4):220–229; 1958.
207. Sugar H.S.: The filtering operations: past, present and future. Int. Ophthalmol. Clin. 21(1):1–13; 1981.
208. Weekers L., Weekers R.: Technique of iridencleisis. Br. J. Ophthalmol. 32:904–910; 1948.
209. March W.F., Gherezghihher T., Koss M.C., Shaver R.P., Heath W.D., Nordquist R.N.: Histological study of neodymium-YAG laser sclerostomy. Arch. Ophthalmol. 103:860–863; 1985.
210. Shields M.B.: Trabeculectomy vs full-thickness filtering operation for control of glaucoma. Ophthalmic Surg. 11:498–505; 1980.
211. Rollet M.: Le drainage au irin de la chambre anterieure contre l'hypertonie et la douleur. Rev. Gen. D'ophthamol 26:209–292: 1907.
212. Zorab A.: “Aqueoplasty.” Ophthalmoscope 11:211–215; 1913.
213. Bock R.H.: Subconjunctival drainage of the anterior chamber by a glass seton. Am. J. Ophthalmol. 33:929–933; 1950.
214. Qadeer S.A.: Acrylic gonio-subconjunctival plates in glaucoma surgery. Br. J. Ophthalmol 38:353–356; 1954.
215. Laval J.: The use of absorbable gelatin film (Gelfilm) in glaucoma filtration surgery. Arch. Ophthalmol 54:677–682; 1955.
216. Honrubia F.M., Gomez M.L.: Surgical treatment of neovascular glaucoma. Trans. Ophthalmol Soc. UK 99:89–91; 1979.
217. Krupin T., Podos S.M., Becker B.: Valve implants in filtering surgery. Am. J, Ophthalmol. 81:232–235; 1976.
218. Troncoso M.U.: Cyclodialysis with the insertion of a metal implant in the treatment of glaucoma. Arch. Ophthalmol 23:270–300; 1940.
219. LaRocca V.: Gonioplasty in glaucoma. Br. J. Ophthalmol 46:404–415; 1962.
220. Molteno A.C.B., Van Roogen M.M.B., Bartholomew R.S.: Implants for draining neovascular glaucoma. Br. J. Ophthalmol. 61:120–125; 1977.
221. Peyman G.A., May D.R., Ericson E.S.: An experimental “aqueous shunt” for the regulation of intraocular pressure. Can. J. Ophthalmol. 9:463–467; 1974.
222. Sarkies N.J., Hitchings R.A.: Silicone tube and gutter in advanced glaucoma. Trans. Ophthalmol Soc. UK 104:133–136; 1985.
223. Lee P.F., Donovan R.H., Schepens C.L.: Effect of an aqueous-venous shunt in the monkey eye. Can. J. Ophthalmol. 3:22–27: 1968.
224. White T.: Glaucoma pump shunt. Glaucoma 7:289–294; 1985.
225. Heuer D.K., Parrish R.K. II, Gressel M.G., Hoddap E., Desjardins D.C., Skuta G.L., Palmberg P.F., Nevarez J.A., Rockwood E.J.: 5-fluorouracil and glaucoma filtering surgery. III. Intermediate follow-up of a pilot study. Ophthalmology 93(12):1537–1546; 1986.
226. Lee D.A., Flores R.A., Anderson P.J., Leong K.W., Teekhasaenee C. Kater A.W., Hertzmark E.: Glaucoma filtration surgery in rabbits using bioerodible polymers and 5-fluorouracil. Ophthalmology 94(12):1523–1530; 1987.
227. Lee D.A., Leong K.W., Panek W.C., ENG C.T., Glasgow B.J.: The use of bioerodible polymers and 5-fluorouracil in glaucoma filteration surgery. Invest. Ophthalmol. Vis. Sci. 29(11):1692–1697; 1988.
228. Kay J.S., Litin B.S., Jones M.A., Frikzkowski A.W., Chvapil M., Herschler J.: Delivery of antifibroblastic agents as adjuncts to filtration surgery – part II. Delivery of 5-fluorouracil and bleomycin in a collagen implant: Pilot study in the rabbit. Ophthalmic Surg. 17:796–801; 1986.
229. McGuigan L.J., Cook D.J., Yablonski M.E.: Dexamethasone, D-penicillamine, and glaucoma filtration surgery in rabbits. Invest. Ophthalmol. Vis. Sci. 27(12):1755–1757; 1986.
230. Joondeph B.C., Peyman G.A., Khoobehi B., Yue B.Y.: Liposome-encapsulated 5-fluorouracil in treatment of proliferative vitreoretinopathy. Ophthal. Surg. 19(4):252–256; 1988.
231. Assil K.K., Lane J., Weinreb R.N.: Sustained release of antimetabolite 5-fluorouridine-5′-monophosphate by multivesicular liposomes. Ophthal. Surg. 19(6):408–412; 1988.
232. Leong K.W., Kost J., Mathiowitz E., Langer R.: Polyanhydrides for, controlled release of bioactive agents. Biomaterials 7:364–371; 1986.
233. Leong K.W., Brott B.C., Langer R.: Bioerodible polyanhydrides as drug carrier matrices: I. Characterization, degradation and release characteristics. J. Biomed. Mater. Res. 19:941–955; 1985.